Brief: Dawnzera Approved In U.S. As First And Only RNA-Targeted Prophylactic Treatment
21/08/2025 17:42
Aug 21 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: DAWNZERA™ (DONIDALORSEN) APPROVED IN THE U.S. AS FIRST AND ONLY RNA-TARGETED PROPHYLACTIC TREATMENT FOR HEREDITARY ANGIOEDEMA IONIS PHARMACEUTICALS INC: DAWNZERA WILL BE AVAILABLE IN U.S. IN COMING DAYS Source text: ID:nBw4q0csla Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors